Previous 10 | Next 10 |
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders...
2024-01-29 13:21:09 ET Gainers: Neximmune ( NEXI ) +94% . Palisade Bio PALI +83% . Rail Vision Ltd ( RVSN ) +68% . Revelation Biosciences ( REVB ) +54% . Mercurity Fintech Holding MFH +34% . J-Long Group Ltd JL +29% . Intelli...
2024-01-26 09:13:32 ET Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last ar...
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase 1 Study is Being Conducted in Collaboration with Ono Pharmaceutical SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Fate Thera...
2023-12-18 09:45:07 ET CSX Corp. (CSX) CSX is trading UP for the last 5 days, and it at trading at $34.33 with volume of 2,174,565 and a one day change of $0.33 (0.96%). CSX Corp. has a 52-week low of 27.60 and a 52-week high of $34.38. The business's 50-day moving average price is ...
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders...
2023-12-12 16:51:29 ET Gainers: Innovative International Acquis ( IOAC ) +24% . EF Hutton Acquisition Corporation ( EFHT ) +5% . Denali Therapeutics ( DNLI ) +4% . SLM Corporation ( SLM ) +4% . BioCryst Pharmaceuticals ( BC...
2023-11-12 12:10:29 ET Summary Fate Therapeutics stock has fallen 50% and lost 90% of its market cap, validating negative stance on the company. Janssen walked away from a partnership deal with Fate, resulting in a huge loss for shareholders. Fate's current pipeline consists o...
2023-11-09 09:00:27 ET More on Fate Therapeutics Fate Therapeutics: Not Now, Maybe Never? Seeking Alpha’s Quant Rating on Fate Therapeutics For further details see: Fate Therapeutics files $300M mixed securities shelf
2023-11-08 21:12:05 ET Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & ...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Stu...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellu...
2024-03-28 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...